



2PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

8

T

3

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/808,538
		Filing Date	March 25, 2004
		First Named Inventor	Shui-on LEUNG et al.
		Group Art Unit	1645
		Examiner Name	Unassigned
		Attorney Docket Number	40923-0060US2
Sheet	1	of	3

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature	/Parithosh Tungaturthi/ (06)	Date Considered (08-2006)	6 28 06
-----------------------	------------------------------	---------------------------------	-------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box  PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/808,538
(use as many sheets as necessary)				Filing Date	March 25, 2004
				First Named Inventor	Shui-on LEUNG et al.
				Group Art Unit	1645
				Examiner Name	Unassigned
Sheet 2		of 3	Attorney Docket Number 40923-0060US2		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
PT	A08	MOUNTAIN et al., "Engineering Antibodies for Therapy", Biotechnology and Engineering Reviews, Intercept Ltd., December 1992, p. 1-142, Vol. 10		
	A09	GRAZIANO et al., "Construction and Characterization of Humanized Anti-y-Ig Receptor type I (FcγRI) Monoclonal Antibody", The Journal of Immunology, The American Association of Immunologists, pp. 4998-5002, November 1995		
	A10	LEUNG et al., "Humanization of an Anti-carcinoembryonic Antigen Anti-Idiotype Antibody as a Tumor Vaccine and for Targeting Applications", Proceedings of the American Association for Cancer Research Annual Meeting, Vol. 37, March 1996, Meeting Info.: 87th Annual Meeting of the American Association for Cancer Research, Washington, D.C., USA; April 20-24, 1996		
	A11	LOSMAN et al., "Generation and Monitoring of Cell Lines Producing Humanized Antibodies", Clinical Cancer Research, pp. 3101s-3105s, October 1999, Vol. 5		
	A12	LOSMAN, et al., Int. J. Cancer, 58:580-584, 1994		
	A13	PRIMUS, et al., Cancer Research, 43:686, 1983		
	A14	JONES et al., Nature, 332:323, 1988		
	A15	RIECHMANN et al., Nature, 332: 323-327, 1988		
	A16	IRVINE et al., Cancer Immunology Immunotherapy, 36:281-292, 1993		
	A17	PIMM et al., Life Sciences, 56(17); 1401-1406, 1995		
	A18	GAIDA et al., Int'l. J. Cancer, 51:459-465, 1992		
	A19	MORRISON et al., Hospital Practice, pp. 65-69, 72-74, 77-78, 80, October 15, 1989		
	A20	EVAN et al., Q J Med. 92:299-307, 1999		
	A21	JAIN, Cancer and Metastasis Reviews, 9:253-266, 1990		

Examiner Signature	/Parithosh Tungaturthi/ (06/28/2006)	Date Considered	6/28/06
--------------------	--------------------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Unique citation designation number.² Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

Approved for use through 10/20/2002. GPO 005-003
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<i>Complete If Known</i>		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/808,538	
		Filing Date	March 25, 2004	
		First Named Inventor	Shui-on LEUNG et al.	
		Group Art Unit	1645	
		Examiner Name	Unassigned	
(use as many sheets as necessary)				
Sheet	3	of	3	
			Attorney Docket Number	40923-0060US2

OTHER PRIOR ART ~ NON PATENT LITERATURE DOCUMENTS

Examiner Signature	/Parithosh Tungaturthi/ (06/2006) Considered	6	26	06
-----------------------	---	---	----	----

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.² Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.